Literature DB >> 29320775

Cholestatic Jaundice as a Paraneoplastic Manifestation of Prostate Cancer Aggravated by Steroid Therapy.

Min Kyu Kang, Jung Gil Park, Heon Ju Lee.   

Abstract

OBJECTIVE: To report a rare case of paraneoplastic jaundice as a manifestation of prostate cancer. CLINICAL PRESENTATION AND INTERVENTION: We report on a case of paraneoplastic syndrome in a 72-year-old man with prostate cancer that manifested with idiopathic jaundice. Although steroids can be used as treatment in patients with prostate cancer, they could exacerbate paraneoplastic jaundice. The jaundice that flared up after treatment with 40 mg prednisone was improved with antiandrogen treatment.
CONCLUSION: Physicians should be aware of the possibility of paraneoplastic jaundice in patients with prostate cancer. Appropriate antiandrogen therapy should be considered for paraneoplastic jaundice in these patients.
© 2018 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Androgen receptor; Bicalutamide; Jaundice; Prednisone; Prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 29320775      PMCID: PMC5968241          DOI: 10.1159/000486717

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  12 in total

1.  Paraneoplastic hepatic dysfunction in metastatic prostate cancer: the role of cytokine dysregulation.

Authors:  Vi Nguyen; Howard Gurney; David van der Poorten
Journal:  J Clin Oncol       Date:  2010-10-12       Impact factor: 44.544

2.  Paraneoplastic liver dysfunction in prostate cancer.

Authors:  Sanjay H Shah
Journal:  J Pain Symptom Manage       Date:  2006-12       Impact factor: 3.612

3.  Stauffer syndrome and prostate carcinoma, two cases in chronic haemodialysis patients.

Authors:  Julie Hinostroza-Yanahuaya; Carmen Mon-Mon; Olimpia Ortega-Marcos; Juan C Herrero-Berron; Milagros Ortiz-Libreros; Ana Vigil-Medina
Journal:  Nefrologia       Date:  2013       Impact factor: 2.033

4.  Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer.

Authors:  C Y Chang; P J Walther; D P McDonnell
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

5.  Idiopathic cholestatic jaundice may be a paraneoplastic manifestation of underlying malignancy: a case of prostate cancer.

Authors:  Akihiro Okano; Masaya Ohana; Fusako Kusumi
Journal:  Clin J Gastroenterol       Date:  2014-04-12

6.  Paraneoplastic jaundice and prostate cancer.

Authors:  Ana Claudia Vieira; Maria Joana Alvarenga; Jose Carlos Santos; Alberto Mello Silva
Journal:  BMJ Case Rep       Date:  2017-04-22

7.  Paraneoplastic cholestasis associated with prostate carcinoma.

Authors:  Mehmet Koruk; Mehmet Büyükberber; Cemil Savaş; Abdurrahman Kadayifçi
Journal:  Turk J Gastroenterol       Date:  2004-03       Impact factor: 1.852

8.  Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma.

Authors:  Apostolos Karakolios; Christos Kasapis; Theofilos Kallinikidis; Panagiotis Kalpidis; Nikolaos Grigoriadis
Journal:  Clin Gastroenterol Hepatol       Date:  2003-11       Impact factor: 11.382

9.  Cholestatic jaundice as a paraneoplastic manifestation of prostate cancer.

Authors:  Tomomi Kuramoto; Hiroya Senzaki; Hiroyuki Koike; Kenji Yamagiwa; Shinobu Tamura; Tokuzou Fujimoto; Takeshi Inagaki
Journal:  Case Rep Urol       Date:  2013-09-29

Review 10.  Role of BioResponse 3,3'-Diindolylmethane in the Treatment of Human Prostate Cancer: Clinical Experience.

Authors:  Yiwei Li; Fazlul H Sarkar
Journal:  Med Princ Pract       Date:  2015-10-27       Impact factor: 1.927

View more
  1 in total

1.  Stauffer's Syndrome in Patient with Metastatic Prostate Cancer.

Authors:  Andris Romašovs; Aldis Puķītis; Viktorija Mokricka; Elina Frolova
Journal:  Case Rep Urol       Date:  2019-04-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.